Baseline risks for stroke, bleeding determine whether LAAO is preferred to anticoagulants for a-fib patients with high bleeding risk
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Aug. 15, 2022 (HealthDay News) -- For selected patients with atrial fibrillation (AF) and higher bleeding risk, left atrial appendage occlusion (LAAO) may be preferred over oral anticoagulation, according to research published online Aug. 16 in the Annals of Internal Medicine.
Derek S. Chew, M.D., from Duke University in Durham, North Carolina, and colleagues examined the optimal strategy for stroke prevention conditional on the risk for ischemic stroke and bleeding among women and men with nonvalvular AF without prior stroke in a decision analysis with a Markov model.
The researchers found that for patients with AF, the baseline risks for stroke and bleeding determined whether LAAO was preferred over anticoagulants. For higher bleeding risk, the combined risks favored LAAO, but at higher stroke risks, that benefit became less certain. For example, LAAO was favored in more than 80 percent of model simulations for CHA2DS2-VASc scores between 2 and 5 at an HAS-BLED score of 5. At lower bleeding risks (HAS-BLED score of 0 to 1), the probability of LAAO benefit in quality-adjusted life-years was limited to patients with lower stroke risks (CHA2DS2-VASc score of 2). The results were consistent in a sensitivity analysis using the ORBIT bleeding score instead of the HAS-BLED score.
"The LAAO strategy was preferred in those with the highest risk for bleeding. However, the benefit became less certain with increasing risk for ischemic stroke and decreasing bleeding risk," the authors write. "This description of LAAO benefit has the potential to improve shared decision making when selecting patients for LAAO."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles